Effect of sitagliptin and glibenclamide on treatment diabetic patients

Comparison of sitagliptin and glibenclamide on inflammatory markers in type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015102824768N1

Enrollment

Registered

2015-12-23

Start date

2015-07-26

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Diabetes mellitus

Interventions

Intervention 1: Intervention group 1: Prescription oral dose of 100 mg of sitagliptin (from company doctor Obeidi), once per day for 12 weeks. Intervention 2: Intervention group 2: Prescription oral d

Treatment - Drugs

Intervention group 1: Prescription oral dose of 100 mg of sitagliptin (from company doctor Obeidi), once per day for 12 weeks.

Intervention group 2: Prescription oral dose of 2.5-20 mg of Glibenclamide (from company kimia drug), once per day for 12 weeks.

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients with type II diabetes; patients treated with metformin; hemoglobin A1c (HbA1c) levels between 7.30%-9%; duration of of type II diabetes less than ten years. Exclusion Criteria: Cancer; uncontrolled heart failure; treatment with nitrates; blood pressure is not controlled; liver disease; systemic inflammatory diseases; infectious diseases; pregnant women and lactating; pancreatitis; hyper triglyceridemia (more than 500 milligrams per deciliter); using the insulin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Body mass index (BMI). Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: By Using the formula: weight (kg) / the square of the height (m).;Hemoglobin A1c (HbA1c) levels. Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.;The serum levels of Lipids. Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.;Fasting blood glucose levels (FBS). Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.;The inflammatory markers such as interleukin-six. Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.;High-sensitivity C-reactive protein levels (HsCRP). Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.;The level of tumor necrosis factor (TNF-alpha). Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.	—

Measure

Time frame

Body mass index (BMI). Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: By Using the formula: weight (kg) / the square of the height (m).;Hemoglobin A1c (HbA1c) levels. Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.;The serum levels of Lipids. Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.;Fasting blood glucose levels (FBS). Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.;The inflammatory markers such as interleukin-six. Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.;High-sensitivity C-reactive protein levels (HsCRP). Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.;The level of tumor necrosis factor (TNF-alpha). Timepoint: Before treatment and after completion of treatment in the twelfth week. Method of measurement: Venous sampling and sent to the laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJavad Hematyar

Ahvaz Jundishapur University of Medical Sciences

hematyardr@gmail.com+98 61 3222 2922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026